Some evidences in prostate cancer have demonstrated that androgens may downregulate TGFBR2 gene expression through a transcriptional mechanism in which DHT suppresses the binding of the transcription factor Sp1 to the TGFBR2 promoter. The gene discussed is SP1; the disease is prostate carcinoma.